|Bid||0.00 x 1000|
|Ask||17.00 x 900|
|Day's Range||10.42 - 11.14|
|52 Week Range||9.60 - 20.75|
|Beta (5Y Monthly)||1.53|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 14, 2022 - Mar 18, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jul 15, 2021|
|1y Target Est||N/A|
Natrunix-SQ, A True Human Antibody Therapy Discovered and Manufactured at XBiotech, Is Aimed as a Breakthrough Treatment for Arthritic DiseaseAUSTIN, Texas, Jan. 26, 2022 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) enrolled the first patient in a randomized, double-blind, placebo-controlled clinical study to evaluate safety and pharmacokinetics of Natrunix-SQ. Natrunix-SQ targets a crucial inflammatory pathway involved in pain and joint destruction in various forms of arthritis. XBiotech be
Moderna CEO Stéphane Bancel joins Yahoo Finance’s Anjalee Khemlani to discuss the development of an Omicron-specific booster shot, global vaccination efforts, data on the effectiveness of the COVID-19 vaccine, and raised forecasts for vaccine sales and production in 2022.
Pfizer CEO Albert Bourla joins Yahoo Finance’s Anjalee Khemlani to discuss the development of a new COVID-19 vaccine that will include protection against Omicron, vaccine production, and the outlook for an Omicron-specific booster.